Source: https://patents.google.com/patent/CN101801436B/en
Timestamp: 2019-04-22 12:38:03
Document Index: 705178788

Matched Legal Cases: ['art 5', 'art 5', 'art 5', 'art 5', 'art 5', 'art 5', 'art 5', 'art 5', 'art 5', 'art 5', 'art 5', 'art 5', 'art 5', 'art 5', 'art 5', 'art 5', 'art 5', 'art 5', 'art 5', 'art 5', 'art 5', 'art 5', 'art 5', 'art 5', 'art 5', 'art 5', 'art 5', 'art 5', 'art 5', 'art.\n3']

CN101801436B - Drug solution-administration system and cannula for administering drug solution - Google Patents
Drug solution-administration system and cannula for administering drug solution Download PDF
CN101801436B
CN101801436B CN2008801062135A CN200880106213A CN101801436B CN 101801436 B CN101801436 B CN 101801436B CN 2008801062135 A CN2008801062135 A CN 2008801062135A CN 200880106213 A CN200880106213 A CN 200880106213A CN 101801436 B CN101801436 B CN 101801436B
CN2008801062135A
CN101801436A (en
外川刚
2007-10-31 Priority to JP2007-284468 priority Critical
2007-10-31 Priority to JP2007284468 priority
2008-05-01 Priority to JP2008119950 priority
2008-05-01 Priority to JP2008-119950 priority
2008-10-31 Application filed by 奥林巴斯株式会社 filed Critical 奥林巴斯株式会社
2008-10-31 Priority to PCT/JP2008/069935 priority patent/WO2009057774A1/en
2010-08-11 Publication of CN101801436A publication Critical patent/CN101801436A/en
2012-10-24 Publication of CN101801436B publication Critical patent/CN101801436B/en
A drug solution-administration system for feeding a drug solution to mammals including humans which comprises a drug solution feeder (1) for feeding the drug solution, a monitor device (9) having a thin and long monitor probe (7) for monitoring an affected part into which the drug solution is to be administered, and a cannula (C) for administering the drug solution at least a part of which is embedded in the body, wherein the cannula (C) for administering the drug solution guides the drug solution fed from the drug solution feeder (1) and the monitor probe (7) into the affected part as described above. Owing to this constitution, it becomes possible to provide in practice a drug solution-feeding system and a cannula for feeding a drug solution whereby the burden on a patient such as bombing can be reduced and the effect of the administration of an anticancer agent can be easily confirmed.
药液投给系统和药液投给用套管 Solution administration system and a medicinal-solution administration cannula
[0001] 本发明涉及将抗癌剂等药液直接且较长期间连续地投给患部的药液投给系统和药液投给用套管。 [0001] The present invention relates to a medicinal solution is continuously administered to the diseased part of the administration system and a medicinal-solution administration cannula anticancer drug solution directly and of longer duration.
[0002] 以往，在投给抗癌剂的情况下，执行如下的计划投药，即：在I周左右反复进行使用点滴和浸透压泵（参照非专利文献I)等经由静脉等例如I日4小时的投药。 [0002] Conventionally, in the case of administration to an anticancer agent, to execute the scheduled administration, namely: repeating a dropper and osmotic pumps (refer to Non-Patent Document I) and the like via a peripheral vein in about I day 4 I like e.g. hours of administration. 然后，经过例如2周的休息期间再重复进行该计划投药，观察上次计划投药中的抗癌剂投给的效果，实施变更在本次计划投药中使用的药液量和药液种类等的处置。 Then, after a rest period of 2 weeks for example for the effect of repeated administration of the anticancer-agent administration in the administration program, the last observation program, and implement the change amount of chemical liquid used in this kind of administration in the Program like disposal.
[0003] 专利文献I :日本特开2006-167298号公报 [0003] Patent Document I: Japanese Patent Publication Laid-Open No. 2006-167298
[0004] 专利文献2 :国际公开第1993/021940号小册子 [0004] Patent Document 2: International Publication No. 1993/021940 pamphlet
[0005]非专利文献 I :Theewes F and Yum SI. Principles of the operationofgenericosmotic pump for the delivery of semisolid or liquid drugformulations. Ann Biomed Eng 1976,4(4) :343-353 [0005] Patent Document I:.. Theewes F and Yum SI Principles of the operationofgenericosmotic pump for the delivery of semisolid or liquid drugformulations Ann Biomed Eng 1976,4 (4): 343-353
[0006] 非专利文献2 :低酸素佑答(二·£石HIF-I活性化調節機構http://www. biology.tohoku. ac. jp/lab-www/moIbio1/hypoxia/main, html [0006] Non-Patent Document 2: A low Sanso Woo (£ · two HIF-I activation stone adjusting mechanism http:... // www biology.tohoku ac jp / lab-www / moIbio1 / hypoxia / main, html
[0007]非专利文献 3:最新医療情報http://kk. kyodo. co. jp/iryo/news/0822supersonic, html [0007] Non-Patent Document 3: The latest medical information http:... // kk kyodo co jp / iryo / news / 0822supersonic, html
[0008] 非专利文献4 :光全用P亡非侵襲生体診断http://www.mext. go. jp/b_menu/shingi/gijyutu/gijyutu3/toushin/07091111/008. htm [0008] Non-Patent Document 4: full light with a biological P noninvasive diagnostic death http: //www.mext go jp / b_menu / shingi / gijyutu / gijyutu3 / toushin / 07091111/008 htm...
[0009] 非专利文献5 ：http://www. invitrogen. co. jp/qdot/qtracker. shtml [0009] Non-Patent Document 5: http:... // www invitrogen co jp / qdot / qtracker shtml.
[0010] 然而，为了确认在上述现有的各计划投药后进行的对患部投给抗癌剂的效果，使用了CT装置等，从而每次进行各计划投药时都受到X线照射，具有不能忽略患者的受照射量的问题。 [0010] However, in order to confirm the affected part of the anti-cancer agent administered to effect the above-described conventional after each scheduled administration, the use of CT apparatus or the like, so that each time the respective programs when subjected to X-ray irradiation were administered, not having ignored by the exposure of the patient's problem.
[0011] 另一方面，由于CT装置是大型，因而设置场所局限于大医院等，并且台数也受限，因此还具有抗癌剂投给效果的确认花费时间且劳力大的问题。 [0011] On the other hand, due to the CT scanner is a large, thus setting limited to large hospitals and other places, and the number is also limited, and therefore also have to spend time confirmation vote for anti-cancer effects and big labor problem.
[0012] 本发明是鉴于上述而作成的，本发明的目的是提供可减轻施加给受照射等的患者的负担并可简单地确认抗癌剂等药液投给效果的药液投给系统和药液投给用套管。 [0012] The present invention is made in view of the above, an object of the present invention to provide a load is applied to reduce the patient receiving irradiation or the like and can easily check the effect of an anticancer agent solution administration system and a medicinal-solution administration solution administration cannula.
[0013] 为了解决上述问题并达到目的，本发明涉及的药液投给系统向包括人在内的哺乳类供给药液，所述药液投给系统的特征在于，所述药液投给系统具有：药液供给装置，其供给药液；观察装置，其具有观察被投给药液的患部的细长的观察探针；以及药液投给用套管，其至少一部分被嵌入到体内，所述药液投给用套管将从所述药液供给装置供给的所述药液和所述观察探针引导到所述患部。 [0013] In order to solve the above problems and achieve the object, a medicinal-solution administration system according to the present invention is to supply the solution to a mammal including a human, the medicinal-solution administration system is characterized in that the medicinal-solution administration system comprising: a liquid supply device supplying liquid; observation means having an elongated observation probe to the diseased part observation medicinal solution is administered; and solution administration cannula, which is at least partially embedded into the body, the chemical solution administration cannula from said feed solution supply means and the observation probe to the diseased part.
[0014] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述药液投给用套管的被投给所述药液的通道和被插入所述观察探针的通道是通用的同一通道，所述药液投给用套管在不同的时机进行所述药液的投给和使用所述观察探针的观察。 [0014] Further, the medicinal-solution administration system according to the present invention, in the invention, wherein the liquid medicine passage administration cannula is administering the medicinal solution and for inserting the observation probe needle channels are common to the same channel, the medicinal-solution administration cannula for administration for the use of chemical and at different timings by the observation of the observation probe.
[0015] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述药液投给用套管的被投给所述药液的通道和被插入所述观察探针的通道是不同通道。 [0015] Further, the medicinal-solution administration system according to the present invention, in the invention, wherein the liquid medicine passage administration cannula is administering the medicinal solution and for inserting the observation probe needle channel are different channels.
[0016] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，被投给所述药液的通道和被插入所述观察探针的通道配置成同心圆状。 [0016] Further, the present invention relates to a liquid administration system, the invention described above, characterized by administering the medicinal solution and the channel for inserting the observation probe are concentrically arranged passages.
[0017] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，被投给所述药液的通道和被插入所述观察探针的通道是平行配置的。 [0017] Further, the present invention relates to a liquid administration system, the invention described above, characterized by administering the medicinal solution and the channel for inserting the observation probe are arranged in parallel channels.
[0018] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述药液投给用套管具有侧面开口部，并从该侧面开口部向所述患部投给所述药液。 [0018] Further, the present invention relates to a liquid administration system, the invention described above, wherein the medicinal-solution administration cannula has a side opening portion, and to cast from the side to the opening portion of the diseased part said liquid.
[0019] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述药液投给用套管在所述侧面开口部的附近设有由所述观察探针进行检测的标志。 [0019] Further, the present invention relates to a liquid administration system, the invention described above, characterized in that said solution administration cannula is provided by the observation probe in the vicinity of the side surface of the opening portion is mark detection.
[0020] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述观察探针是超声波探针，所述标志反射由所述超声波探针发出的超声波。 [0020] Further, the present invention relates to a liquid administration system, the invention described above, wherein the observation probe is an ultrasonic probe, the marker reflects ultrasound generated by the ultrasound probe.
[0021] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述标志是气泡。 [0021] Further, the present invention relates to a liquid administration system, the invention described above, wherein the marker is a bubble.
[0022] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述药液投给用套管能以该药液投给用套管的轴为中心转动。 [0022] Further, the present invention relates to a liquid administration system, the invention described above, wherein the medicinal-solution administration cannula to the drug solution can be administered to the rotary shaft as the center of the sleeve.
[0023] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述侧面开口部在周向上设有多个。 [0023] Further, the present invention relates to a liquid administration system, the invention described above, characterized in that said side opening portion provided in the circumferential direction a plurality.
[0024] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述观察探针在被收容于所述药液投给用套管内被插入该观察探针的通道内的状态下，能以该观察探针的轴为中心转动。 [0024] Further, the medicinal-solution administration system according to the present invention, in the invention, characterized in that the observation channel is accommodated in the medicinal-solution administration cannula is inserted into the inner of the observation probe in the probe a state in which, as the shaft can rotate about the observation probe.
[0025] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述观察探针是超声波探针，并具有：设在探针前端的气球，以及将流体插入到所述气球内的插入单元。 [0025] Further, the medicinal-solution administration system according to the present invention, in the invention, wherein the observation probe is an ultrasonic probe, and comprising: a balloon provided at the probe tip, and inserted into the fluid the inner balloon insertion unit.
[0026] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述观察探针是成像探针。 [0026] Further, the medicinal-solution administration system according to the present invention, in the invention, wherein the observation probe is an imaging probe.
[0027] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述成像探针一并使用造影剂。 [0027] Further, the present invention relates to a liquid administration system, the invention described above, characterized in that said contrast agent imaging probe used together.
[0028] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述成像探针是荧光探针。 [0028] Further, the present invention relates to a liquid administration system, in the above invention, wherein the imaging probe is a fluorescent probe.
[0029] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述成像探针是发光探针。 [0029] Further, the present invention relates to a liquid administration system, the invention described above, characterized in that said luminescent probe is an imaging probe.
[0030] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述成像探针是超声波探针。 [0030] Further, the present invention relates to a liquid administration system, in the above invention, wherein the imaging probe is an ultrasonic probe.
[0031] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述观察探针是生物传感器探针。 [0031] Further, the medicinal-solution administration system according to the present invention, in the invention, wherein the observation probe is a bio-sensor probe.
[0032] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述观察探针具有标志，所述药液投给用套管具有检测部，该检测部在被插入所述观察探针的通道内检测所述标志。 [0032] Further, the medicinal-solution administration system according to the present invention, in the invention, wherein the observation probe includes a marker, the medicinal-solution administration cannula includes a detecting portion, the detection portion is inserting the observation probe detects the passage of the flag. [0033] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述检测部检测所述观察探针相对于所述药液投给用套管的轴的相对的周向和相对于该轴的相对的推力方向的位置。 [0033] Further, the present invention relates to a liquid administration system, the invention described above, characterized in that said detecting unit detects the observation relative to the probe relative to the axis of the medicinal-solution administration cannula is and a position with respect to the circumferential direction of the shaft opposite to the thrust direction.
[0034] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述标志是磁标 [0034] Further, the medicinal-solution administration system according to the present invention, in the invention, wherein said marker is a magnetic scale
[0035] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述药液投给系统具有细长的穿刺针，该穿刺针被插入到所述药液投给用套管内，并投给所述药液，所述穿刺针具有标志，所述药液投给用套管具有检测部，该检测部在被插入所述穿刺针的通道内检测所述标志。 [0035] Further, the medicinal-solution administration system according to the present invention, in the invention, wherein the medicinal-solution administration system having an elongated puncture needle, the puncture needle is inserted into the medicinal-solution administration with the inner sleeve, and administering the medicinal solution, the puncture needle includes a marker, the medicinal-solution administration cannula includes a detecting unit, the detecting unit detects the marker in the puncture needle is inserted into the channel.
[0036] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述检测部检测所述穿刺针相对于所述药液投给用套管的轴的相对的周向和相对的推力方向的位置。 [0036] Further, the medicinal-solution administration system according to the present invention, in the invention, wherein opposing circumferential detecting section detects the puncture needle with respect to the axis of the medicinal-solution administration cannula and opposite to the thrust direction position.
[0037] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述标志是磁标 [0037] Further, the medicinal-solution administration system according to the present invention, in the invention, wherein said marker is a magnetic scale
[0038] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述穿刺针在前端附近具有自由弯曲的弯曲部。 [0038] Further, the present invention relates to a liquid administration system, in the above invention, wherein the puncture needle has a curved portion in the vicinity of the free front end is bent.
[0039] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述穿刺针是由至少2个以上的导管构成的多层导管，内侧导管在外侧导管的轴线方向上自由滑动地被插入，内侧导管从外侧导管的前端部自由突出，在至少I个导管的前端部形成有弯曲部，内侧导管具有比外侧导管小的弯曲刚性，所述弯曲部弯曲形成为使内侧导管在所述外侧导管内处于能弹性变形的弹性限度内。 [0039] Further, the medicinal-solution administration system according to the present invention, in the invention, wherein the puncture needle is a multi-layer pipe formed with at least two of the catheter, the inner catheter in the axial direction of the outer pipe is slidably inserted into the inner conduit protruding from the free end of the outer conduit is formed at least in the distal portion of the conduits I bent portion, the inner conduit having a smaller flexural rigidity than the outer pipe, the bent portion formed by bending such that the inner conduit is elastically deformable within the elastic limit within the outer conduit.
[0040] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述观察装置显示并输出由所述检测部检测出的所述穿刺针相对于所述药液投给用套管的轴的相对的周向和相对的推力方向的位置。 [0040] Further, the medicinal-solution administration system according to the present invention, in the invention, characterized in that the observation device displays and outputs the puncture needle detected by the detecting unit with respect to the medicinal-solution administration a position opposing to the circumferential direction and a relative thrust direction with the axis of the sleeve.
[0041] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述观察装置的显示输出是将所述药液投给用套管的位置和所述穿刺针相对于该药液投给用套管的位置重叠在所述患部的观察结果上来显示。 [0041] Further, the present invention relates to a liquid administration system, the invention described above, characterized in that the observation device is output to the display of the liquid administered to the location of the needle cannula and a relative to this solution administration cannula in a position superimposed onto the diseased part of the observations display.
[0042] 并且，本发明涉及的药液投给系统，在上述发明中，其特征在于，所述药液供给装置具有：药液贮存器，其至少贮存药液，并将该药液供给药液投给侧；可变流量泵，其将压出所述药液贮存器内的药液的驱动液可变地排出到所述药液贮存器；驱动液贮存器，其贮存所述驱动液；以及控制单元，其控制所述可变流量泵的排出流量，以使每单位时间的药液投给量为期望投给量。 [0042] Further, the medicinal-solution administration system according to the present invention, in the invention, wherein said chemical liquid supply apparatus comprising: a liquid reservoir that accommodates at least medicinal solution and the drug solution supply It was administered to the side; a variable flow pump, which was driven out of the liquid pressure within the liquid reservoir is discharged to the variable chemical reservoir; drive-liquid reservoir, which the driving liquid reservoir ; and a control unit which controls the discharge flow rate of the variable flow pump so that the liquid per unit time to the amount administered for a desired amount of administration.
[0043] 并且，本发明涉及的药液投给用套管被嵌入到体内，能将从药液供给装置供给的药液引导到患部并将所述药液投给患部，并且能将观察被投给所述药液的患部的所述观察装置的观察探针引导到所述患部附近来进行所述患部的观察，所述药液投给用套管的特征在于，该药液投给用套管具有侧面开口部，从该侧面开口部向所述患部投给所述药液，并在所述侧面开口部的附近设有由所述观察探针检测的标志。 [0043] Further, the present invention relates to administering the drug solution to be embedded into the body with a cannula, can guide liquid from the chemical liquid supplied from the supply means to the diseased part and a diseased part of the medicinal-solution administration, and can be observed the observation probe to the diseased part observation means administering the medicinal solution and guided to the vicinity of the diseased part to observe the diseased part, the medicinal-solution administration cannula is characterized in that the solution administration the sleeve having a side opening portion, the opening portion from the side administering the medicinal solution to the diseased part, and a mark observed by the detection of the probe in the vicinity of the side surface of the opening portion.
[0044] 并且，本发明涉及的药液投给用套管，在上述发明中，其特征在于，所述观察探针是超声波探针，所述标志反射由所述超声波探针发出的超声波。 [0044] Further, the present invention relates to a drug solution administration cannula, in the above invention, wherein the observation probe is an ultrasonic probe, the marker reflects ultrasound generated by the ultrasound probe.
[0045] 并且，本发明涉及的药液投给用套管，在上述发明中，其特征在于，所述标志是气泡。 [0045] Further, the present invention relates to a drug solution administration cannula, in the above invention, wherein the marker is a bubble.
[0046] 并且，本发明涉及的药液投给用套管，在上述发明中，其特征在于，所述药液投给用套管能以该药液投给用套管的轴为中心转动。 [0046] Further, the present invention relates to a drug solution administration cannula, in the above invention, wherein the medicinal-solution administration cannula to the drug solution can be administered to a center axis of rotation of the sleeve .
[0047] 并且，本发明涉及的药液投给用套管，在上述发明中，其特征在于，所述侧面开口部在周向上设有多个。 [0047] Further, the present invention relates to a drug solution administration cannula, the invention described above, characterized in that said side opening portion provided in the circumferential direction a plurality.
[0048] 并且，本发明涉及的药液投给用套管，在上述发明中，其特征在于，被投给所述药液的通道和被插入所述观察探针的通道是通用的同一通道。 [0048] Further, the present invention relates to a drug solution administration cannula, the invention described above, characterized in that the medicinal solution is administered to the channel for inserting the observation probe channel is a common channel of the same .
[0049] 并且，本发明涉及的药液投给用套管，在上述发明中，其特征在于，被投给所述药液的通道和被插入所述观察探针的通道是不同通道。 [0049] Further, the present invention relates to a drug solution administration cannula, the invention described above, characterized by administering the medicinal solution and the channel for inserting the observation probe channel are different channels.
[0050] 并且，本发明涉及的药液投给用套管，在上述发明中，其特征在于，被投给所述药液的通道和被插入所述观察探针的通道配置成同心圆状。 [0050] Further, the present invention relates to a drug solution administration cannula, the invention described above, characterized in that the medicinal solution is administered to the channel and the channel for inserting the observation probe are concentrically arranged .
[0051] 并且，本发明涉及的药液投给用套管，在上述发明中，其特征在于，被投给所述药液的通道和被插入所述观察探针的通道是平行配置的。 [0051] Further, the present invention relates to a drug solution administration cannula, the invention described above, characterized by administering the medicinal solution and the channel for inserting the observation probe are arranged in parallel channels.
[0052] 并且，本发明涉及的药液投给用套管，在上述发明中，其特征在于，所述药液投给用套管具有：前端套管，其设在所述患部侧；连接套管，其设在所述药液供给装置的药液供给口侧；以及连接部，其连接所述前端套管和所述连接套管，通过取下所述连接部来将所述观察探针插入到所述前端套管内。 [0052] Further, the present invention relates to a drug solution administration cannula, in the above invention, wherein the medicinal-solution administration cannula includes: a cannula distal end, which is provided on the side of the diseased part; connector sleeve, which is provided in said chemical solution supply port side of the supply device; and a connection portion which connects the end cannula to the connection cannula, by removing the connecting portion to the observation probe needle is inserted into the front end of the inner sleeve.
[0053] 并且，本发明涉及的药液投给用套管，在上述发明中，其特征在于，所述药液投给用套管具有：前端套管，其设在所述患部侧；连接套管，其设在所述药液供给装置的药液供给口侧；以及连接部，其连接所述前端套管和所述连接套管，通过仅对所述连接部中被插入所述观察探针的通道开设开口来将所述观察探针插入到所述前端套管内。 [0053] Further, the present invention relates to a drug solution administration cannula, in the above invention, wherein the medicinal-solution administration cannula includes: a cannula distal end, which is provided on the side of the diseased part; connector sleeve, which is provided in said chemical solution supply port side of the supply device; and a connection portion which connects the end cannula to the connection cannula, is inserted through the observed only in the connecting portion defines an opening for passage of the probe to the observation probe is inserted into the end cannula.
[0054] 并且，本发明涉及的药液投给用套管，在上述发明中，其特征在于，所述前端套管具有：圆筒状管，其前端开放；以及内栓部件，其堵塞所述圆筒状管的前端。 [0054] The present invention relates to the medicinal-solution administration cannula, in the above invention, wherein the cannula has a distal end: a cylindrical tube having an open distal end; and an inner plug member which clogging the distal end of said cylindrical tube.
[0055] 并且，本发明涉及的药液投给用套管，在上述发明中，其特征在于，所述前端套管还具有引导该前端套管的圆筒状的外筒套管。 [0055] Further, the present invention relates to a drug solution administration cannula, in the above invention, wherein the end cannula further includes a cylindrical outer cylinder guides the end cannula sleeve.
[0056] 根据本发明，由于能将从药液供给装置供给的药液引导到患部并将所述药液投给患部，并且能将观察装置的观察探针引导到患部附近并进行所述患部的观察，因而可减轻对受照射等的患者施加的负担，并可简单进行抗癌剂投给的效果确认。 [0056] According to the present invention, since the guide from the chemical liquid can be supplied from the supply means to the diseased part and a diseased part of the medicinal-solution administration and the observation probe observation apparatus can be guided to the vicinity of the diseased part and diseased part observations, thereby to reduce the burden on the patient receiving irradiation or the like is applied, and can be simply administered for verifying the effect of an anticancer agent.
[0057] 图I是示出本发明的实施方式I涉及的药液投给系统的概要结构的示意图。 [0057] Figure I is a diagram illustrating an embodiment of the present invention is liquid I according to the schematic configuration of a system vote.
[0058] 图2是示出在图I所示的药液投给系统内插入了观察探针的状态的示意图。 [0058] FIG. 2 is a diagram showing the observation probe is inserted in the drug solution shown in Figure I a state administration system.
[0059] 图3是示出药液供给装置的详细结构的框图。 [0059] FIG. 3 is a block diagram illustrating a detailed configuration of the liquid supply apparatus.
[0060] 图4是示出药液贮存器内的药液和驱动液之间的边界部分附近的状态的图。 [0060] FIG. 4 is a diagram showing a state in the vicinity of a boundary portion between the driving liquid and the liquid in the liquid reservoir.
[0061] 图5是示出图I所示的药液投给系统的变形例的概要结构的示意图。 [0061] FIG. 5 is a diagram showing a schematic configuration of a modification of the embodiment shown in FIG. I administered the drug solution to the system.
[0062] 图6是示出图5所示的前端套管的一例的剖视图。 [0062] FIG. 6 is a sectional view showing the front end of the sleeve shown in FIG. 5 shows.
[0063] 图7是示出图5所示的前端套管的另一例的剖视图。 [0063] FIG. 7 is a sectional view of another embodiment of the end cannula illustrated in FIG. 5 shows.
[0064] 图8是示出本发明的实施方式2涉及的药液投给系统的概要结构的示意图。 [0064] FIG. 8 is a diagram illustrating an embodiment of the present invention, the drug solution 2 according to the schematic configuration of a system vote.
[0065] 图9是示出图8所示的前端套管的前端附近的详细结构的横剖视图。 [0065] FIG. 9 is a cross sectional view showing a detailed configuration in the vicinity of the distal end of the end cannula illustrated in FIG. 8 shows. [0066] 图10是图9所示的前端套管的AA线剖视图。 [0066] FIG. 10 is a front end of the sleeve along the line AA shown in FIG. 9 a sectional view.
[0067] 图11是示出根据癌细胞的状态变更前端套管的开口部位置的一例状态的说明图。 [0067] FIG. 11 is an explanatory view showing an example of a state change of the opening position of the distal end portion of the sleeve according to the state of cancer cells.
[0068] 图12是示出利用气泡实现了图8所示的反射部的前端套管的前端附近结构的纵首1J视图。 [0068] FIG. 12 schematically illustrates the configuration of the bubble to achieve the longitudinal tip end portion near the front end of the reflector 8 shown in FIG. 1J view of the first sleeve.
[0069] 图13是示出在图8所示的前端套管上设有气球的结构的图。 [0069] FIG. 13 is a diagram showing the structure of a balloon provided on the front end of the sleeve shown in Fig.
[0070] 图14是示出设有多个开口部的前端套管的结构的剖视图。 [0070] FIG. 14 is a sectional view of the distal sleeve is provided with a plurality of opening portions of the structure shown.
[0071] 图15是示出将药液通道和探针通道形成为同心圆状的前端套管的结构的剖视图。 [0071] FIG. 15 is a cross-sectional view illustrating the configuration of a distal end of the sleeve concentric liquid channel and the probe passage is formed.
[0072] 图16是示出将药液通道和探针通道平行形成的前端套管的结构的纵剖视图。 [0072] FIG. 16 is a longitudinal front end of the sleeve structure formed of parallel liquid channels and the probe channel cross-sectional view shown.
[0073] 图17是图16所示的前端套管的BB线剖视图。 [0073] FIG. 17 is a BB line of the end cannula 16 illustrated in cross-sectional view in FIG.
[0074] 图18是示出在图8所示的前端套管的外周设有外筒套管的状态的剖视图。 [0074] FIG. 18 is a sectional view showing a state where an outer cylindrical sleeve in the outer circumference of the end cannula illustrated in FIG. 8 shows.
[0075] 图19是示出图8所示的前端套管的形成一例的图。 [0075] FIG. 19 is a diagram showing an example of the formation of the end cannula illustrated in FIG. 8.
[0076] 图20是示出本发明的实施方式涉及的药液投给装置的概要结构的示意图。 [0076] FIG. 20 is a schematic diagram illustrating a schematic configuration of a liquid embodiment of the present invention relates to the administration device.
[0077] 图21是示出图20所示的引导套管、穿刺针以及检测探针的结构的图。 [0077] FIG. 21 is a diagram showing the guide sleeve 20 shown in FIG configuration of a detection probe and the puncture needle.
[0078] 图22是图21的AA线剖视图。 [0078] FIG. 22 is an AA sectional view of line 21.
[0079] 图23是示出在引导套管内插入了穿刺针的状态的剖视图。 [0079] FIG. 23 is a cross-sectional view illustrating a puncture needle is inserted in the guide sleeve state.
[0080] 图24是示出观察装置主体部的结构的框图。 [0080] FIG. 24 is a block diagram showing a configuration of the observation apparatus main body portion.
[0081] 图25是示出三维观察图像的一例的图。 [0081] FIG. 25 is a diagram illustrating an example of a three-dimensional observation image.
[0082] 图26是示出使用检测探针和穿刺针的药液投给的一例的图。 [0082] FIG. 26 is the use of a detection probe and the puncture needle for administration of drug solution shown example of FIG.
[0083] 标号说明 [0083] DESCRIPTION OF REFERENCE NUMERALS
[0084] I :药液供给装置；2 :连接套管;3，3a，3b :连接部;4，54，54a，74，84，104 :前端套管；5 :患部；6 :活体；7，107 :观察探针；8 :观察装置主体；9 :观察装置；10 :药液贮存器；11 :磁标志；12 :电气渗透流泵；13 :驱动液贮存器；20 :磁线传感器；21 :控制部；21a :活体信息检测部；21b :流量变化检测部；21c :泵控制部；22 :输入输出部；23 :存储部；23a :活体信息和流量关系存储部；24 :活体信息传感器；30 :驱动液；31 :药液；32a，32b :油；33a，33b :空气；44a，45a :药液通道；44b, 45b :探针通道；54b :硅树脂；57 :超声波探针；57a,107b :收发部;61，61a〜61c，91 :开口部；62，62a〜62c，63，92 :反射部；71 :气球；72 :供给孔；100 :外筒套管；107a, 110a, 130a :标志;110，130 :穿刺针;lll，llla 〜Illd :编码器；112，133 :开口部；117 :驱动部；121 或”电路；122 :计数部；123 :推力位置计算部；12 [0084] I: chemical liquid supply apparatus; 2: connecting sleeve; 3,3a, 3b: connection portion; 4,54,54a, 74,84,104: end cannula; 5: affected area; 6: in vivo; 7 , 107: observation probe; 8: observation apparatus main body; 9: observation device; 10: liquid reservoir; 11: magnetic marker; 12: electrical osmotic flow pump; 13: drive-liquid reservoir; 20: magnetic line sensor; 21: control unit; 21a: living body information detecting unit; 21b: flow change detection unit; 21c: a pump control unit; 22: input and output unit; 23: a storage unit; 23a: biometric information and traffic relationship storage unit; 24: biological information sensor; 30: drive liquid; 31: liquid; 32a, 32b: oil; 33a, 33b: air; 44a, 45a: liquid passage; 44b, 45b: probe channel; 54b: silicone; 57: ultrasonic probe ; 57a, 107b: a transceiver section; 61,61a~61c, 91: opening portion; 62,62a~62c, 63,92: reflection portion; 71: balloon; 72: supply hole; 100: an outer cylindrical casing; 107a, 110a, 130a: flag; 110,130: the puncture needle; lll, llla ~Illd: encoder; 112, 133: opening portion; 117: drive unit; 121 or "circuits; 122: counting portion; 123: position calculating unit thrust ; 12 4 ：径向位置计算部；125 :显示处理部；130 :穿刺针；131 :外侧导管；132 :内侧导管；C :药液投给用套管；CA:癌细胞。 4: radial position calculating portion; 125: display processing unit; 130: puncture needle; 131: outer conduit; 132: inner catheter; C: solution administration cannula; the CA: a cancer cell.
[0085] 以下，参照附图详细说明本发明涉及的药液投给系统和药液投给用套管的优选实施方式。 [0085] Hereinafter, with reference to the detailed description of the present invention relates to a liquid administration system, and the solution of the preferred embodiment cannula administered to the accompanying drawings. 另外，本发明不受本实施方式的限定。 Further, the present invention is not limited to the present embodiment.
[0086](实施方式I) [0086] (Embodiment I)
[0087] 图I是示出本发明的实施方式I涉及的药液投给系统的概要结构的示意图。 [0087] Figure I is a diagram illustrating an embodiment of the present invention is liquid I according to the schematic configuration of a system vote. 在图I中，该药液投给系统是这样的系统：可将数十ml程度的药液，例如氟脲嘧啶（5-FU)等抗癌剂在I星期左右的长期间内连续且集中地排出到人体等活体6内的癌症等的患部5来进行计划投药，并可在该计划投药后观察患部。 In FIG. I, the medicinal-solution administration system is a system: the degree of several tens ml liquid, e.g. fluorouracil (5-FU) and other anticancer agents over a long period of about I week continuously and concentrated discharged to the affected area of ​​cancer in the human body and other living 5 6 to program administration, and the affected area is observed after administration plan.
[0088] 该药液投给系统具有：药液供给装置1，其排出药液；超声波诊断装置等观察装置9，其具有观察患部5的状态的超声波探针等观察探针7 ;以及药液投给用套管C，其将药液供给装置I排出的药液引导到患部5，并将观察探针7引导到患部5。 [0088] The medicinal-solution administration system comprising: a chemical liquid supply apparatus 1, which liquid is discharged; ultrasonic diagnostic apparatus observation apparatus 9, having observed the state of the affected area is observed ultrasound probe 7 probe 5 and the like; and liquid administration cannula C, the solution supply means to guide liquid discharged I diseased part 5, the guide and the observation probe 7 to the diseased part 5. 药液投给用套管C具有：连接套管2，其设在药液供给装置I侧；前端套管4，其设在患部5侧并嵌入到活体内；以及连接部3，其对连接套管2和前端套管4进行连接，并且在分离时出现观察探针7的插A 口。 Solution administration cannula C includes: a connecting sleeve 2, which is provided in the chemical liquid feeding device I side; distal sleeve 4, which is provided in the side of the diseased part 5 and fitted into a living body; and a connecting portion 3, which is connected the front end of the sleeve 2 and the sleeve 4 is connected, and appears insertion port a of the observation probe 7 in the separation. 并且，观察装置9如上所述具有观察探针7，并具有观察装置主体8，该观察装置主体8具有显示由观察探针7取得的观察信息的未图示的显示部和对观察信息进行处理的未图示的处理部等。 Further, as described above observation device 9 includes an observation probe 7 and an observation apparatus main body 8, the observation apparatus main body 8 having a display (not shown) of the observation information acquired by the observation probe 7 and a display unit for processing observation information processing unit (not shown) or the like. 另外，药液供给装置I可以嵌入到活体6内。 Further, chemical liquid supply apparatus I may be embedded into the living body 6.
[0089] 如图I所示，在前端套管4被插入到活体6内、且前端套管4的前端部分到达了患部5的内部的状态下，经由连接部3和连接套管2从药液供给装置I向患部5按计划投给药液。 [0089] FIG I, the distal end portion is inserted into the living body 6 and the end cannula 4 has reached the front end of the sleeve 4 inside the affected area in the state 5, the connecting portion and the connecting sleeve 3 from the cartridge 2 via liquid supply apparatus according to plan I administered medicinal solution to the diseased part 5. 在该计划投药结束的时候，如图2所示，连接部3被分离，将观察探针7从前端套管4侧的连接部3b的插入口插入到前端套管4的前端部分，观察患部5的状态。 When the end of the administration of the program, as shown in FIG connector portion 3 are separated, the observation probe 7 to the sleeve 4 from the front end side of the insertion opening of the connector portion 3b of the front end portion inserted into the end cannula 4, the affected area is observed 2 state 5. 例如，在观察装置9是超声波诊断装置、且观察探针7是超声波探针的情况下，可得到患部5的超声波断层像。 For example, in the observation device 9 is an ultrasonic diagnostic apparatus, and the case where the observation probe 7 is an ultrasonic probe, the ultrasonic tomographic image obtained affected part 5.
[0090] 这里，参照图3说明药液供给装置I的详细结构。 [0090] Here, with reference to FIG. 3, a detailed structure of a chemical liquid supply apparatus I. 如图3所示，药液供给装置3具有：药液贮存器10，其贮存药液；驱动液贮存器13，其贮存有压出药液的驱动液；以及电气浸透流泵12，其设在驱动液贮存器13和药液贮存器10之间，压出用于压出药液的驱动液。 3, chemical liquid supply apparatus 3 includes: a liquid reservoir 10, which reservoir liquid; drive-liquid reservoir 13, which reservoir has a chemical liquid pressure driving liquid; and the electro-osmotic flow pump 12, which is provided between the drive-liquid reservoir 13 and the liquid reservoir 10, a pressure for pressing the drive liquid out of the liquid. 另外，期望的是，驱动液使用超纯水等。 Further, it is desirable that the driving liquid ultrapure water and the like. 电气浸透流泵12的动作原理是，电浸透材料（多孔质体）的细孔内的表面带负电，在表面附近，正离子过剩，由于从外部施加的电场而使正离子受力并移动，使驱动液产生流动，从而排出驱动液。 Operation principle of the electro-osmotic flow pump 12, the inner surface of the pores electrical impregnated material (porous body) is negatively charged in the vicinity of the surface, the excess positive ions, an electric field applied from outside and the forced movement of positive ions, the driving fluid flow is generated, thereby discharging drive liquid. 因此，通过使电场强度变化，可使驱动液的排出量变化。 Thus, by varying electric field strength, can change the discharge amount of the drive liquid.
[0091] 药液贮存器10是将内径相同的细径管严密地卷绕成相同直径的线圈状来配置的药液贮存器，在管内部贮存有抗癌剂等药液。 [0091] The liquid reservoir 10 is the same as the inner diameter of the small diameter tube tightly wound the same diameter medical-solution reservoir configured in a coil shape, the inner tube has an anticancer drug solution reservoir. 该管的电气浸透流泵12侧流入驱动液。 The electrical permeation flow pump tube 12 flows into the drive liquid side. SP，通过驱动液的压出，间接地将药液从药液贮存器10压出。 The SP, pushed out by the drive liquid, the liquid from the indirect medical-solution reservoir 10 is pressed out.
[0092] 这里，药液贮存器10在驱动液30的前端部分配置有磁标志11。 [0092] Here, liquid reservoir 10 is disposed at a front end portion of the magnetic marker 11 of the driving liquid 30. 如图4所示，该磁标志被夹在油32a、32b之间，而且外侧被夹在空气33a、33b之间，在其外侧充满驱动液30和药液31。 4, the magnetic marker is sandwiched between oil 32a, 32b, and the outside air is sandwiched 33a, between 33b, on its outside and filled with drive liquid 30 liquid 31. 并且，在药液贮存器10的沿轴向的外部表面配置有沿轴向的磁线传感器20。 Further, the external surface of the medical-solution reservoir 10 is disposed in the axial direction along the axial direction of the magnetic line sensor 20. 其结果，磁标志11随着药液排出而移动，该移动的磁标志11的移动量或者移动状态由磁线传感器20检测。 As a result, the drug solution discharge with magnetic marker 11 is moved, the movement of the magnetic marker movement amount or the movement state 11 is detected by the magnetic line sensor 20.
[0093] 并且，药液供给装置I具有活体信息传感器24。 [0093] Further, the chemical liquid supply apparatus I has a biological-information sensor 24. 活体信息传感器24检测作为投药对象的活体6的活体信息。 The biological information sensor 24 detects as the subject of administration in vivo biological information 6. 活体信息例如是心跳数、血压等一般指标、以及在急性肝障碍时上升的YGTP、ALT、AST等的逸脱酶、血中氧分压的Pa02、炎症标志的CRP等，是与投给药液的感受性、针对对象部位的作用、以及针对非对象部位的副作用相关的信息。 Usually biological information, for example, the heart rate index, blood pressure, and Yi rising in acute hepatic disorder YGTP, ALT, AST and the like decarboxylase, Pa02 blood oxygen partial pressure, CRP and other markers of inflammation, is administered to a liquid susceptibility, site of action for the object, as well as the side effects of non-target site for related information.
[0094] 而且，药液供给装置I具有：控制部21，其根据磁线传感器20的检测结果和活体信息传感器24的检测结果，至少进行电气浸透流泵12的驱动液的流量控制；输入输出部22，其对药液供给装置I进行各种输入指示或设定、以及进行显示等的输出；以及存储部23，具有活体信息和流量关系存储部23a，其存储由活体信息传感器24检测出的活体信息值和药液的单位时间流量之间的关系。 [0094] Further, the chemical liquid feeding device I includes: a control unit 21, based on a detection result of the detection result of the magnetic line sensor 20 and the biometric information sensor 24, at least the flow control electro-osmotic flow drive liquid pump 12; O section 22, to the chemical liquid supply apparatus that performs various input instructions or settings I, and outputs a display or the like; and a storage unit 23, the biometric information having a relationship storage unit and flow 23a, which stores the biological information detected by the sensor 24 the relationship between the flow rate per unit time of the biological information and the value of the liquid. 另外，活体信息和流量关系存储部23a可以具有单位时间流量的时间变化即时间曲线。 Further, the biometric information storage unit 23a, and flow rate relationship may change with time, i.e. time per unit time flow rate curve.
[0095] 控制部21的活体信息检测部21a根据由活体信息传感器24检测出的值，检测活体信息值。 [0095] 21a based on the value detected by the biological information sensor 24 detects biological information value of the biological information detector unit 21 of the control unit. 并且，控制部21的流量变化检测部21b通过由磁线传感器20检测出磁标志11的位置来检测药液的流量变化。 Then, the flow change detection unit 21b of the control unit 21 detects the change in liquid flow rate through the position of the magnetic marker 11 is detected by the magnetic line sensor 20. 控制部21的泵控制部21c根据由活体信息检测部21a检测出的活体信息值和由活体信息和流量关系存储部23a保持的活体信息和流量关系，求出单位时间流量，并控制由电气浸透流泵12排出的驱动液的流量、换句话说是药液的流量，以使由流量变化检测部21b检测出的流量变化成为求出的单位时间流量。 The pump control unit control section 21 21c according detected by the biological information detecting unit 21a biological information value, and biometric information and flow relationship by the biometric information, and the flow rate relation storage unit 23a holding the obtained unit time flow rate, and controls the impregnated by the electrical drive liquid flow discharged flow pump 12, in other words, the liquid flow rate to the flow rate change by the flow change detection unit 21b detects the flow rate per unit time be determined.
[0096] 另外，上述的控制部21根据由活体信息传感器24取得的活体信息控制药液的流量，然而也可以不设置活体信息传感器24而进行计划投药的流量控制。 [0096] Further, the control unit 21 according to the flow of liquid is controlled by the biological sensor 24, the biometric information acquired information, however, may not be provided a living body information sensor 24 performs flow control program administration. [0097] 在本实施方式I中，使用药液投给用套管C将药液仅投给患部5的管路即前端套管4作为观察探针7的插入路而共用，因而可通过简单的结构，使观察探针7容易到达作为观察对象的患部5，并能直接且可靠地观察患部5。 [0097] In the present embodiment, I, a solution administration cannula C administered to only the diseased part liquid line 5, i.e. the end cannula 4 as the observation probe 7 is inserted into the common path, thus by simple the structure of the observation probe 7 to easily reach the diseased part 5 as an observation target, and can be directly observed and the diseased part 5 reliably. 特别是，由于观察探针7的前端到达患部5的内部，因而可从患部5的内侧观察患部5，可详细观察患部5的状态。 In particular, since the front end of the observation probe 7 reaches the inside of the diseased part 5, which can be observed diseased part 5 from the inside of the diseased part 5, a state can be observed diseased part 5 in detail.
[0098] 并且，与使用CT装置等的患部观察相比，当然能进行简单的观察，由于不受X线照射，因而可消除由观察给活体带来的不良影响。 [0098] Further, with the use of the affected area was observed as compared to CT apparatus or the like, can of course, a simple observation, since the X-ray irradiation is not, thus to eliminate the adverse effects observed by the living body brought. 因此，可使用观察探针7随时且高频度地进行患部5的观察。 Thus, 7 can be performed at any time and frequency of the diseased part 5 is observed using the observation probe.
[0099] 而且，由于药液仅被投给患部5，因而难以产生药液投给的副作用等。 [0099] Further, since the liquid medicine is administered to only the diseased part 5, it is difficult to produce the medicinal-solution administration side effects. 并且，由于药液从患部5的内部被投给，因而可对患部5整体进行药液投给，能可靠且有效地对患部5进行药液投给。 Further, since the liquid medicine is administered to the diseased part 5 from the inside, which can be administered to the affected part 5 chemical whole, can be reliably and efficiently administered to the diseased part 5 is liquid.
[0100] 这里，参照图5说明实施方式I的变形例。 [0100] Here, the modification of the embodiment described with reference to FIG. 5 I. 在上述实施方式I中，将前端套管4内的药液管路用作观察探针的插入路，然而在该变形例中，在与前端套管4对应的前端套管44内设置有药液通过的药液通道44a和供观察探针7插入的探针通道44b。 I In the above embodiment, the liquid passage pipe is inserted into the end cannula used in the observation probe 4, but in this modification, the front end of the sleeve 4 corresponding to the front end of the inner sleeve 44 is provided with a drug was passed through a chemical liquid supply passage 44a and the observation probe 7 is inserted a probe channel 44b.
[0101] 即使在前端套管44内独立具有这样的药液通道44a和探针通道44b，观察探针7的前端也与实施方式I 一样，能容易到达患部5。 [0101] Even in the end of the pin 44 has a separate liquid channel 44a and the probe channel 44b, the front end of the observation probe 7 is also the same as in Embodiment I, can easily reach the diseased part 5.
[0102] 前端套管44的具体结构例如图6所示，形成同心圆状的双层管，将由内侧管所形成的空间用作被插入观察探针7的探针通道44b，将形成在内侧管与外侧管之间的空间用作药液通过的药液通道44a。 Specific structure [0102] for example, the end cannula 44 illustrated in FIG. 6, formed concentric double tube, the tube is formed by the inner space of the probe as the probe is inserted into the channel 7 of the observed 44b, formed on the inside the space between the tube and the outer tube is used as the chemical liquid through liquid medicine passage 44a. 另外，在内侧管与外侧管之间形成有保持内侧管的保持部44c。 Further, between the inner tube and the outer tube holding portion is formed inside of the tube 44c. 通过设置该保持部44c，可通过压出等使前端套管44成形，容易形成前端套管44。 By providing the holding portions 44c, so that the end cannula 44 can be molded by extrusion and the like, the end cannula 44 is easily formed.
[0103] 在该情况下，形成有2个药液通道44a，可执行使不同药液对应于各药液通道44a来供给的多剂并用疗法。 [0103] In this case, there is formed two liquid passages 44a, so that the different chemical perform multiple doses corresponding to the respective medicinal-solution channel 44a and is supplied with therapy. 该多剂并用疗法一并使用多个抗癌剂来投药，不期望将各抗癌剂混合，而是通过使用多个药液通道44a，可防止各抗癌剂的混合来投药。 The multi-agent and used together with a plurality of anticancer therapies administered to undesirable mixing the anticancer agent, but by using a plurality of liquid channels 44a, prevents mixing of the anticancer agent be administered. 反之，在将各药液通道44a用作I个药液通道的情况下，只要对前端套管44的前端侧和连接部3b侧的保持部44c的至少一部分开设切口等，形成I个药液通道即可。 Conversely, in the case where each of the chemical liquid channel 44a as the I-channel, as long as at least a portion of the holding portion 3b of the front end side and distal end side connecting portion 44c of the sleeve 44 defines a cutout and the like, a liquid form I channel can be.
[0104] 并且，如图7所示，可以将药液通道45a和探针通道45b在前端套管44内邻接并平行配置。 [0104] As shown in FIG. 7, the medicinal-solution channel 45a and the probe channel 45b adjacent the front end of the sleeve 44 and arranged in parallel.
[0105](实施方式2) [0105] (Embodiment 2)
[0106] 下面，说明本发明的实施方式2。 [0106] Next, Embodiment 2 of the present invention. 在上述实施方式I中，前端套管4、44的前端设有开口，而在本实施方式2中，如图8所示，堵塞前端套管54的前端，设置从前端附近沿径向投给药液的开口部61，将反射部62设置在与开口部61的位置对应的位置处，该反射部62发射观察探针7产生的物理量。 I In the above embodiment, the front end of the end cannula 4, 44 is provided with an opening, whereas in the second embodiment, shown in Figure 8, the front end blockage of the end cannula 54, is provided near the radial direction from the front end to the administration the opening portion of the liquid 61, the reflecting portion 62 is provided at a position corresponding to the position of the opening portion 61, which portions 62 emitted reflecting physical quantity generated by the observation probe 7. 其他结构与实施方式I相同，对相同构成部分附上相同标号。 Other embodiments of formula I and the same structure, the same reference numerals to the same components.
[0107] 通过具有这样的结构，能在周向上选择距离开口部61的药液投给位置。 [0107] By having such a structure, the drug solution can be selected from the opening portion 61 in the circumferential direction to a location administration. 并且，插入的观察探针的前端定位容易。 And, positioning the distal end of the observation probe is inserted easily. 而且，由于设有反射部62，因而通过用观察探针7检测反射部62，可容易得知开口部61的位置。 Further, since the reflecting portion 62, thereby detecting the reflected portion through the probe 7 by observation 62 can easily know the position of the opening portion 61. 另外，优选的是，将开口部61和反射部62对应于各药液通道44a来设置。 Further, it is preferable that the opening portion 61 and the reflective portions 62 corresponding to the respective medicinal-solution channel 44a is set. · ·
[0108] 具体地说，如图9和图10所示，在前端套管54的前端附近的径向上设有开口部61，从该开口部61向患部5投给药液。 [0108] Specifically, as shown in FIGS. 9 and 10, the radially outer ends of the end cannula 54 is provided near the opening portion 61, from the liquid to the opening portion 61 to the diseased part 5 administered. 在观察探针7是超声波探针57的情况下，在开口部61附近设有由反射超声波的金属钼实现的反射部62。 In the case where the observation probe 7 is an ultrasonic probe 57, provided with a reflective metallic molybdenum portion implemented by ultrasonic waves reflected in the vicinity of the opening portion 6162. 通过使超声波探针57的收发部57a旋转，并使其朝轴向移动来检测反射部62，可知在该反射部62的位置（轴向和周向）上存在开口部61。 By rotating the ultrasound probe 57 transmitting and receiving unit 57a, and allowed to move axially toward the detecting reflector 62, seen in the opening portion 61 is present on the position (axial and circumferential) portion of the reflector 62. 通过将该开口部61的位置与所观察的患部5的状态进行对比，能可靠变更与患部5的状态对应的药液投给位置，即开口部61的位置。 The state position by the opening portion 61 with the observed diseased part 5 of contrast, state of the diseased part can be reliably changed with 5 corresponding to position solution administration, i.e., the position of the opening portion 61. 例如图11 (a)所示，在作为药液投给位置的开口部61附近癌细胞CA消失、且在药液投给位置的背面附近癌细胞CA生长的情况下，可使前端套管54旋转180°，如图11(b)所示，可使开口部61朝向癌细胞CA生长的区域有效地输送药液。 For example in FIG. 11 (a), in the vicinity of the opening portion 61 as the position of the medicinal-solution administration disappearance of cancer cells CA, and in the case of cancer cells grown in the vicinity of the back surface CA solution administration position, the end cannula 54 can rotation of 180 °, FIG. 11 (b), the can 61 toward the opening portion of the growth of cancer cell area CA efficiently deliver liquid.
[0109] 另外，在使用超声波探针57作为观察探针7的情况下，由于反射部62只要反射超声波即可，因而例如图12所示，可以采用由气泡形成的反射部63。 [0109] Further, in the case where the ultrasonic probe 57 as the observation probe 7, since the reflection portion 62 can be as long as the reflected ultrasonic wave, as shown in FIG. 12 Thus, for example, may be reflective portion 63 formed by the bubble. 该反射部63只要在形成前端套管54时，在反射部63的位置处封入空气即可。 When the reflective portion 63 is formed at the front end as long as the sleeve 54, air can be sealed at the position of the reflective portion 63. 该反射部63由于在前端套管54的内部或外部不具有突起，因而可顺利地进行前端套管向活体6内的插入或者超声波探针57的插入。 Since the reflective portion 63 in the front end of the sleeve 54 inside or outside does not have protrusions, so that the end cannula can be smoothly inserted into the living body 6 or the ultrasound probe 57 is inserted.
[0110] 并且，在使用超声波探针57的情况下，当在前端套管74与超声波探针57的前端表面之间形成空间时，由于空间而使超声波反射，从而不能观察患部5，因而如图13所示，可以设置覆盖超声波探针57的前端部分的气球71、以及使连接部3b和气球71内部相连通的供给孔72，在观察时经由供给孔72向气球71内充满PBS (磷酸缓冲生理盐水），使得不会形成空气的空间。 [0110] Further, in the case of using an ultrasonic probe 57, when the front end surface is formed in the space between the sleeve 74 and the distal end of the ultrasonic probe 57, the ultrasonic waves reflected due to the space, and thus can not observe the diseased part 5, so as As shown in FIG. 13, an ultrasonic probe may be provided to cover the front end portion 57 of the balloon 71, and the connecting portion 3b and the balloon supply hole 71 communicating the interior 72, 72 filled with PBS (phosphate into the balloon 71 via the supply hole when viewed buffered saline), so that the air space is not formed. 另外，不限于PBS，也可以充满例如纯水。 Further, PBS is not limited to, for example, may be filled with purified water.
[0111] 而且，在上述实施方式2中，设置I个开口部61和I个反射部62、63，然而如图14所示，也可以在圆周上设置多个开口部61a〜61c，并在与这些开口部61a〜61c的位置分别对应的位置处设置多个反射部62a〜62c。 [0111] Further, in the above embodiment 2, the opening portion 61 provided the I and I reflecting portions 62 and 63, however as shown, may be provided a plurality of openings 14 in the circumferential 61a~61c and at a position with a position of the opening portions respectively corresponding to 61a~61c plurality of reflecting portions 62a~62c. 并且，这些开口部61a〜61c和反射部62a〜62c的位置可以设置在沿轴向分别错开的位置上。 Then, the position of the opening portion and the reflective portion 62a~62c 61a~61c may be disposed at axially offset positions, respectively. 通过该轴向的位置错开，可以识别各开口部61a〜61c。 By shifting the position of the axial direction, each opening portion can be identified 61a~61c. 并且,关于各开口部61a〜61c的识别,可以使反射部62a〜62c的大小等变化来识别。 And, on each opening portion 61a~61c recognition, it can make changes in the size of the reflector portion 62a~62c identified.
[0112] 另外，在本实施方式2中，也可以独立具有药液通道44a和探针通道44b。 [0112] Further, in the embodiment 2 of the present embodiment, it may have a separate liquid channels 44a and the probe channel 44b. 例如，如图15所示，经由保持部44e形成同心圆状的双层管，在前端套管84内形成药液通道44a和探针通道44b。 For example, as shown in FIG 15, a double tube formed concentrically through the holding portion 44e, is formed liquid passages 44a and 44b in the front end of the probe channel cannula 84. 在图15中，形成有多个开口部61a〜61c和反射部62a〜62c。 In FIG 15, is formed with a plurality of openings and the reflection portion 61a~61c 62a~62c.
[0113] 同样，如图16和图17所示，可以使药液通道45a和探针通道45b邻接并平行配置在前端套管94内。 [0113] Similarly, as shown in FIGS. 16 and 17, so that liquid can probe channel 45a and channel 45b arranged in parallel and adjacent to the front end of the sleeve 94. 在该情况下，设有I个开口部91和反射部92。 In this case, an opening portion 91 provided the I 92 and the reflective portion.
[0114] 另外，在上述实施方式1、2中，前端套管表面均与活体接触，然而不限于此，如图18所示，可以进一步设置覆盖前端套管的外部表面的外筒套管100。 [0114] Further, in the above-described embodiments 1 and 2, the front end surface of the sleeve are in contact with the living body, but is not limited thereto, shown in Figure 18, it may be further provided to cover the outer surface of the distal end of the outer cylindrical sleeve 100 the sleeve . 在该情况下，在活体6内先嵌入外筒套管100，在该外筒套管100内插入前端套管54。 In this case, in the living body 6 fitted to the outer cylindrical sleeve 100, the outer tubular sleeve 54 is inserted into the end cannula 100.
[0115] 并且，在上述实施方式1、2中，在前端套管4被嵌入到活体6内的状态下作了说明，在将前端套管4嵌入到活体6内的情况下，如图19所示，当使用穿刺针110时容易嵌入。 [0115] In the above described embodiments 1 and 2, the front end of the sleeve 4 is fitted into the 6 state in which the living body has been described, in the case where the end cannula 4 6 fitted to the living body, FIG. 19 shown, when the puncture needle 110 is easy to insert. 在使用该穿刺针110的情况下，首先如图19(a)所示，将前端套管54a和穿刺针110从前端侧一体地插入到活体6内，该前端套管54a是圆筒状，其前端朝向圆筒中心形成锥形，该穿刺针110被插入到该前端套管54a内，其前端侧从前端套管54a的前端突出，且前端形成为锥形。 In the case where the puncture needle 110, first, as shown in FIG 19 (a), the end cannula 54a and the puncture needle 110 is inserted from the front end side of the integrally to the living body 6, the end cannula 54a is cylindrical, its front end to form a tapered cylinder center, the puncture needle 110 is inserted into the end cannula 54a, protruded from the front end side of the distal end cannula 54a, and the tip is tapered. 之后，在前端到达患部5的时候取下穿刺针110(参照图19(b))。 Thereafter, when the leading end reaches the diseased part 5 of the puncture needle 110 is removed (see FIG. 19 (b)). 在该情况下，当取下了穿刺针110时，插入观察探针7，通过反射部62和患部5的检测可进行前端位置的确认。 In this case, when removing the puncture needle 110, inserting the observation probe 7 can be confirmed by detecting the position of the distal end portion 62 and the reflection of the diseased part 5. 之后，如图19(c)所示，将作为内栓部件的硅树脂54b从连接部3b侧插入到前端开口内，堵塞前端部分，从而形成实施方式2所示的前端套管54。 Thereafter, as shown in FIG 19 (c), the silicon resin 54b is inserted into the inner member from the stopper portion 3b is connected to the inner side of the distal end opening, the distal end portion blocked, so as to form the embodiment 2 of the end cannula 54 illustrated. 另外，在不形成硅树脂54b的情况下，成为图19(b)所示的前端套管4,如实施方式I所示。 Further, in the case where the silicone resin 54b is not formed, and becomes in FIG. 19 (b) as shown in the front end of the sleeve 4, as shown in embodiment I.
[0116] 另外，在上述实施方式I中，作为观察探针7的一例使用超声波探针57作了说明，然而不限于此，观察探针7只要是能观察患部5即可，例如可以使用OCT (光相干断层计）。 [0116] Further, in the above-described embodiments of formula I, as one case of the observation probe 7 is an ultrasonic probe 57 has been described, but is not limited thereto, as long as the observation probe 7 to the diseased part 5 is observed, for example, can use the OCT (optical coherence tomography unit). 而且，可以使用内窥镜探针。 Also, the endoscopic probe can be used. 在使用内窥镜探针的情况下，例如通过使内窥镜探针的前端沿轴向移动来获知患部5的外缘，从而可得知形状变化，除此之外，通过观察患部5的颜色变化，还可把握在超声波断层像中观察不到的患部5的血管新生状态。 In the case of using the endoscopic probe, for example, be learned by the distal end of the endoscopic probe is moved axially outer edge of the diseased part 5 so that the shape change may, in addition, by observing the diseased part 5 color change, may not grasp the ultrasonic tomographic image is observed in the state of the affected part 5 of angiogenesis.
[0117](实施方式3) [0117] (Embodiment 3)
[0118] 下面说明本发明的实施方式3。 [0118] The following description of the embodiments of the present invention. FIG. 本实施方式3涉及的药液投给装置具有：穿刺针110，其与连接套管2连接，并将药液供给装置I排出的药液投给患部5 ；以及前端套管104，其与前端套管4对应，将穿刺针110引导到患部5，并将观察探针7引导到患部5，而且检测穿刺针110和观察探针7相对于该前端套管104的相对位置。 Embodiment 3 relates to liquid administration to the device having: a puncture needle 110, which is connected to the connecting sleeve 2, and the discharged chemical liquid supply apparatus I solution administration diseased part 5; and the end cannula 104, with the distal end the sleeve 4 corresponding to the puncture needle 110 to guide the diseased part 5, the guide and the observation probe 7 to the diseased part 5, the puncture needle 110 and the detection probe and the observation of the relative position with respect to the end cannula 104 7. 在前端套管104中，设在与药液供给装置I侧连接的连接套管2的前端侧的穿刺针110和观察探针7经由连接部3b的插入口被交替插入。 In the end cannula 104, the puncture needle 110 provided in the sleeve and connected to the distal end observation side 2 is connected to the chemical liquid supply apparatus I side probe 7 are alternately inserted through the insertion opening of the connector portion 3b. 即，在实施方式I中，前端套管4具有药液投给功能和观察探针的引导机构；而在本实施方式3中，穿刺针110担负药液投给功能，前端套管104担负对穿刺针110和观察探针7的引导机构。 That is, in embodiments I, the distal sleeve 4 and the guide mechanism functions observation probe having a medicinal-solution administration; in the embodiment 3 of the present embodiment, the puncture needle 110 to assume the function solution administration, the end cannula 104 on the shoulder the puncture needle 110 and the observation probe 7 of the guide means.
[0119] 并且，观察装置9具有与观察探针7对应的观察探针107和驱动部117，在利用该驱动部117使观察探针107沿前端套管104的轴线方向步进或定速移动的同时，取得观察图像。 [0119] Further, the observation device 9 has the observation probe 7 corresponding to the observation probe 107 and a drive unit 117, using the driving unit 117 so that the observation probe 107 along the axial direction of the distal end 104 of the sleeve or fixed speed movement step at the same time, to obtain observation images. 并且，观察装置主体8具有显示由观察探针107取得的超声波断层像等观察信息的未图示的显示部和对观察信息进行处理的未图示的处理部等。 Further, the observation apparatus main body 8 having a display (not shown) of the observation information acquired by the observation probe 107 of the ultrasonic tomographic image display unit and the like (not shown) and the like of the processing unit for processing observation information. 其他结构与实施方式I相同，对相同构成部分赋予相同标号。 Other embodiments of formula I and the same structure, the same reference numerals to the same components.
[0120] 这里，参照图21说明前端套管104、穿刺针110以及观察探针7的概要结构。 [0120] Here, described with reference to the end cannula 104, the puncture needle 110 and the observation probe 7 a schematic structure 21 of FIG. 另夕卜，图22是图21的AA线剖视图，图23是示出在前端套管104内插入了穿刺针110的状态的剖视图。 Another Bu Xi, FIG. 22 is a sectional view of AA line 21, FIG. 23 is a cross-sectional view of the puncture needle 110 is shown inserted in the front end of the sleeve 104. 在图21〜图23中，在前端套管104的前端附近的内壁具有在周向上分布4个、且分别在周向上间隔90度地配置的磁编码器111 (Illa〜Illd)。 In FIG. 21~ 23, the inner wall 104 near the distal end cannula 4 has a distribution in the circumferential direction, and each interval in the circumferential direction a magnetic encoder 111 (Illa~Illd) is arranged 90 degrees. 这些编码器Illa〜Illd各自的检测结果被输出到外部的观察装置主体8。 These encoders Illa~Illd respective detection result is output to the external observation apparatus main body 8.
[0121] 另一方面，穿刺针110和观察探针107都是前端为针状，在前端附近的外表面，分别以预定间距Zl在轴线方向上配置有沿周向具有约90度分布的多个磁标志110a、107a。 [0121] On the other hand, the puncture needle 110 and the observation probe 107 are the front end of the needle, the outer surface near the front end, respectively, arranged in a predetermined pitch Zl to the axial direction of about 90 degrees having a plurality of circumferentially distributed magnetic markers 110a, 107a. 因此，在穿刺针110或观察探针107被插入到前端套管104内的情况下，如图22所示，编码器Illa〜Illd中的任意I个以上的编码器检测标志110a，通过该标志IlOa的检测，可得知穿刺针110相对于前端套管104的相对的周向（径向方向)的位置。 Thus, in the case where the cannula is inserted into the distal end 104 of the puncture needle 110 or the observation probe 107, as shown in, any of the above encoder Illa~Illd encoder detects the I flag 110a in FIG. 22, through the flag IlOa detection can know the position of the puncture needle 110 with respect to the end cannula 104 relative to the circumferential direction (radial direction). 例如，在图22中，可得知穿刺针110相对于前端套管104而言标志IlOa位于约45度的位置。 For example, in FIG. 22, the puncture needle 110 can be learned with respect to the end cannula 104 in terms of flag IlOa located approximately 45 degrees. 并且，如图23所示，编码器Illa〜Illd从穿刺针110的前端侧的标志Ml开始依次检测，由于从被投给药液的前端的开口部112起标志Ml的轴线方向的位置是已知、且标志IlOa间的间距Zl是已知，因而可根据编码器111的位置得知穿刺针110前端的相对的轴线方向（推力方向）的位置。 And, 23, the encoder sequentially Illa~Illd flag Ml is detected from the front end side of the puncture needle 110, due to the axial direction from the distal end portion of the opening for administering the drug solution 112 from the position flag Ml is known, and the mark pitch between IlOa Zl are known, thus knows the location of the puncture needle 110 opposite to the front end of the axial direction (thrust direction) from the position encoder 111. 例如，在图23中，可得知穿刺针110的前端位于距离编码器111为（Z0+Z1X2)的位置。 For example, in FIG. 23, the distal end of the puncture needle 110 that is located at a distance encoder 111 (Z0 + Z1X2) position. 另外，也能与穿刺针110同样地检测观察探针107的相对的径向方向的位置和推力方向的位置。 Further, the position and the thrust direction opposite to the radial direction of the probe 107 can be detected in the same observation of the puncture needle 110.
[0122] 如图24所示，编码器Illa〜Illd的检测输出被送到观察装置主体8内，在观察装置主体8内，检测穿刺针110或观察探针107的相对的径向方向位置和推力方向位置，可将由观察探针107观察到的三维断层像和穿刺针110的前端位置重叠显示。 [0122] shown in Figure 24, the detection output is supplied to the encoder Illa~Illd observation apparatus main body 8, in the observation apparatus main body 8, the puncture needle 110 or the observation of the detection probe 107 relative radial-direction position and the position of the thrust direction, the position of the probe tip can be observed by the three-dimensional tomographic image 107 and the puncture needle 110 is displayed superimposed observed.
[0123] 在图24中，在由“或”电路121检测出编码器Illa〜Illd中的至少一个的情况下，由各编码器Illa〜Illd检测出的信息由计数部122计数，推力位置计算部123根据该计数结果，计算穿刺针110的前端相对于前端套管104的位置（开口部112的位置）或者观察探针107的前端相对于前端套管104的位置（收发部107b的位置），并输出到显示处理部125。 [0123] In FIG. 24, at least one is detected by the encoder Illa~Illd "or" circuit 121, each encoder Illa~Illd information detected by the counting unit 122 counts, thrust position calculating the result of the count unit 123, calculates (the position of a transceiver unit 107b) of the distal end of the puncture needle 110 with respect to the end cannula 104 (the position of the opening portion 112) or the tip of the probe was observed with respect to the distal end 107 of the sleeve 104 and output to the display processing section 125. 另一方面，径向位置计算部124根据各编码器Illa〜Illd的检测结果，计算配置有标志IlOa或107a的径向方向位置，将该结果输出到显示处理部125。 On the other hand, the radial position calculating unit 124 based on the detection results of the encoders Illa~Illd calculated IlOa or flag 107a is disposed in the radial direction position, and outputs the result to the display processing section 125. 这里，预先或者之后将观察图像从观察探针107输入到显示处理部125。 Here, in advance or after the observation image from the observation probe 107 is input to the display processing section 125. 显示处理部125根据观察探针107相对于前端套管104的相对的推力方向和相对的径向方向，将观察图像显示并输出到相对于前端套管104的三维坐标上。 The display processing unit 125 according to the observation probe 107 relative to the thrust direction and a radial direction relative to the distal end of the sleeve 104, and outputs the observation image is displayed on the three-dimensional coordinates with respect to the end cannula 104. 然后，在求出穿刺针110相对于前端套管104的相对的推力方向和相对的径向方向的情况下，将该穿刺针110的前端推力位置和开口部112的径向方向重叠显示在观察图像上。 Then, in a case where the puncture needle 110 is obtained with relative thrust direction and the relative radial direction with respect to the end cannula 104, the position of the thrust and radial direction leading end portion of the opening 110 of the puncture needle 112 is displayed superimposed observation the image on.
[0124] 例如，如图25所示的显示画面那样，在显示画面上，基于超声波断层像的处理对象5被三维显示，穿刺针110前端的推力方向位置Z和径向方向位置0重叠在该三维显示的图像上进行显示输出。 [0124] For example, a display screen as shown in FIG. 25, on the display screen, based on the ultrasonic tomographic image of the processing target 5 is three-dimensional display, the front end of the puncture needle 110 in the thrust direction and the radial position in the Z-direction position of the overlap 0 three-dimensional image is displayed on the output display. 由此，能可靠且简单得知穿刺针110的药液投给的位置和方向，可针处理对象5进行有效的药液投给。 Thus, the chemical liquid that can be reliably and easily puncture needle 110 vote for a position and orientation, the needle may be processed 5 effective solution administration.
[0125] 这里，示出使用穿刺针110和观察探针107的药液投给和观察的一例。 [0125] Here, a used puncture needle 110 and the observation probe solution administration and one case of 107 was observed. 在图26中，首先前端套管104的前端被穿刺到处理对象5的附近，在该前端套管104内插入观察探针107 (图26(a))。 In FIG 26, first, the front end of the end cannula 104 is punctured into the vicinity of the processing target 5, and the observation probe 107 is inserted (FIG. 26 (A)) in the front end of the sleeve 104. 观察探针107通过驱动部117以步进或固定速度移动到处理对象5侧，伴随该移动，在收发部107b旋转的同时取得超声波断层像。 The observation probe 107 or a stepping drive unit 117 fixed to the moving speed of the processing target 5 side, accompanying this movement, the ultrasonic tomographic image acquired at the same time rotated by the transceiver portion 107b. 另一方面，伴随该观察探针107的移动，利用编码器Illa〜Illd求出观察探针107相对于前端套管104的相对的推力方向位置和相对的径向方向位置。 On the other hand, along with the movement of the observation probe 107, determined by the encoder Illa~Illd the observation probe 107 relative thrust-direction position and the relative radial-direction position with respect to the end cannula 104. 在使观察探针107移动的同时，通过检测超声波断层像和该超声波断层像的摄影时的相对的推力方向位置和相对的径向方向位置，可获得相对于前端套管104而言的相对坐标上的三维观察图像。 In that the observation probe 107 is moved while the ultrasonic tomographic image and by detecting the relative position of the thrust direction and the radial direction relative to the imaging position of the ultrasonic tomographic image can be obtained in terms of relative coordinates with respect to the end cannula 104 on the three-dimensional observation image.
[0126] 之后，将穿刺针110插入到前端套管104内，将药液投给处理对象5 (图26(b))。 After [0126], the puncture needle 110 is inserted into the end cannula 104, the medicinal-solution administration to the processing target 5 (FIG. 26 (b)). 这里，如上所述，穿刺针110相对于前端套管104的相对的推力方向位置和相对的径向方向位置由编码器Illa〜Illd求出，而且在三维观察图像上逐次重叠显示，因而能可靠且容易调整穿刺针110相对于处理对象5的药液投给位置和方向。 Here, as described above, the puncture needle 110 with relative thrust-direction position and radial direction position relative to the distal end 104 of the sleeve is determined by the encoder Illa~Illd, but also in the three-dimensional observation image displayed superimposed sequentially, thereby reliably and easily adjust the puncture needle 110 with respect to the chemical treatment of the object 5 to the location and orientation of administration.
[0127] 然后，当结束一定期间且一定量的药液投给时，再次将观察探针7插入到前端套管104内，取得药液投给后的处理对象5a的三维观察图像（图26(c))。 [0127] Then, when the end of a certain period and a certain amount of solution administration, once again the observation probe 7 is inserted into the end cannula 104, to obtain three-dimensional observation image of the processing target 5a after the medicinal-solution administration (FIG. 26 (c)). 之后，进一步将穿刺针110插入到前端套管104内，进行对处理对象5a的药液投给（图26(d))。 Thereafter, the puncture needle 110 is further inserted into the end cannula 104, a drug solution is administered to the processing target 5a (FIG. 26 (d)). 在该情况下，由于在未图示的监视器上重叠显示有处理对象5a的三维观察图像和穿刺针110的图像，因而在以三维观察图像观察处理对象5a的形状和穿刺针110的位置的同时，参照三维观察图像上的穿刺针110的位置，将投给位置和投给方向引导到可最有效地向该处理对象5a投给药液的位置。 In this case, since the monitor (not shown) is displayed superimposed image of the three-dimensional observation image and the puncture needle 110 of the processing target 5a, and thus the position of the processing target three-dimensional observation image of the observation 5a and shape of the puncture needle 110 Meanwhile, referring to the puncture needle position on three-dimensional image 110 is observed, the position of the guide may be most effectively administered to the processing target 5a to vote for the medicinal solution and administered to the position direction. 由此，即使在处理对象5a的形状随时间变化的情况下，也能有效地继续对处理对象5a进行药液投给。 Accordingly, even when the shape of the processing target 5a over time, can continue to be processed efficiently for solution administration 5a. 并且，如图26(d)所示，在获得处理对象5a的观察图像的时刻，参照处理对象5a的形状，使用前端倾斜定位的穿刺针130来取代直动的穿刺针110，从而可以不进行侵害性的前端套管104的插拔。 Further, the shape of FIG. 26 (d), at time to obtain the observation image of the processing target 5a, 5a of the reference processed, an inclined front end of the puncture needle 130 is positioned to replace the linear motion of the puncture needle 110, which can not be the front end of the sleeve 104 of the plug invasive.
[0128] 另外，穿刺针130使用专利文献I中记载的多层导管。 [0128] Further, the puncture needle using the multilayer conduit 130 described in Patent Document I. 即，穿刺针130是由至少2个以上的导管构成的多层导管，内侧导管132在外侧导管131的轴线方向上自由滑动地被插入，从外侧导管131的前端部自由突出，在至少I个导管的前端部形成弯曲部，内侧导管132具有比外侧导管131小的弯曲刚性，弯曲部弯曲形成为使内侧导管132在外侧导管131 内处于能弹性变形的弹性限度内。 That is, the puncture needle 130 is a multilayer pipe made of at least two of the catheter, the inner catheter 132 is slidably inserted in the axial direction of the outer pipe 131, projecting from the free end of the outer catheter 131, at least one I a curved distal portion of the catheter, the inner catheter 132 smaller than the outer pipe 131 having bending rigidity, the bent portion is bent to the inner tube 132 is formed within the elastic limit is elastically deformable in the outer conduit 131. 另外，在该穿刺针130的前端附近设有与标志IlOa等对应的标志130a。 Further, in the vicinity of the distal end of the puncture needle 130 is provided with a sign corresponding to a sign like IlOa 130a.
[0129] 作为穿刺针130的另一可能的变形例，穿刺针130还能采用这样的结构：将针安装在小型内窥镜的前端，经由内窥镜的通道供给药液。 [0129] As another puncture needle 130 possible modification, the puncture needle 130 can also be adopted such a configuration: a small needle mounted on the distal end of the endoscope, the endoscope via the liquid supply passage. 在该情况下，在内窥镜的前端附近设置自由弯曲（自由折弯）的弯曲部，可自由变更针的方向。 In this case, in the vicinity of the distal end of the endoscope is provided consisting of a curved (bent free) of the bent portion, may change the direction of the free needle.
[0130] 这里，上述的观察探针107是利用作为成像探针的超声波探针来获得三维观察图像的，然而不限于此，例如可以使用生物传感器探针来取代观察探针107，求出处理对象5、5a的状态分布，显示药液投给的最佳位置。 [0130] Here, the above-described observation probe 107 obtains the three-dimensional observation image by the ultrasonic probe as an imaging probe, but not limited to, for example, using a biosensor probe unsubstituted observation probe 107 obtains the processing state of the object 5,5a distribution, display the best solution administration's position. 例如，利用低氧状态使HIF-I (Hypoxia-Inducible Factor-1,缺氧诱导因子-I)和HLF (HIF-1 a Like Factor,HIF-I a样因子）等的复制因子激活，从而诱导：作为红血球生长因子的红细胞生成素(EPO),作为血管内皮生长因子的VEGF(Vascular Endothelial GrowthFactor,血管内皮细胞生长因子）及其收容体，在血管中作用的内皮素-1，纤维蛋白溶酶原激活因子阻碍因子-1，诱导型一氧化氮合成酶，TOGF-B，铁代谢相关的铁传递蛋白及其收容体，血浆铜蓝蛋白，血红素加氧酶-I，对邻苯二酚胺合成的速率决定阶段进行催化的酪氨酸氢氧化酶，将葡萄糖输入到细胞的葡萄糖输送体（GLUTl)，作为解糖酶的磷酸果糖激酶、醛缩酶A、烯醇化酶等的多种蛋白质和酶（参照非专利文献2)。 For example, to make use of hypoxia HIF-I (Hypoxia-Inducible Factor-1, hypoxia inducible factor -I) and HLF (HIF-1 a Like Factor, HIF-I a like factor) such as replication factor activation, thereby inducing : as red blood cell growth factor erythropoietin (EPO), VEGF as vascular endothelial growth factor (vascular endothelial growthFactor, vascular endothelial growth factor) and containing body, acting in the vascular endothelin-1, plasmin activator obstruction factor 1, inducible nitric oxide synthase, TOGF-B, associated with iron metabolism and transferrin containing body, ceruloplasmin, heme oxygenase -I, catechol the rate-determining step synthesis of amines by catalytic tyrosine hydroxyl enzyme, glucose inputted to the glucose transporting cell body (Glutl), as a solution carbohydrases phosphofructokinase, aldolase a, enolase more like proteins and enzymes (see Non-Patent Document 2). 得知在肿瘤中心部附近处于低氧状态，通过将由于这些低氧状态而高发的蛋白质和酶等检测为低氧状态的生物标志，可进行准确捕捉到肿瘤中心附近的有效投药。 That in the vicinity of the center portion of the tumor is hypoxic state, since these by hypoxia and high protein and enzymes for the detection of biomarker hypoxia, and can be effectively administered to accurately capture the vicinity of the center of the tumor.
[0131] 并且，在使用超声波探针的情况下，优选的是将微气泡一并用作造影剂（参照非专利文献3)。 [0131] Further, in the case of using an ultrasonic probe, it is preferable to collectively as microbubble contrast agents (see Non-Patent Document 3). 当把该微气泡用作造影剂时，可检测例如0. 2_直径的血管，可根据由癌化产生的血管新生来判定肿瘤位置。 When the microbubbles as contrast agents which can be detected, for example, 0. 2_ vascular diameter may be determined according to the location of the tumor angiogenesis resulting from cancerous.
[0132] 而且，可以取代观察探针107而使用作为成像探针的光检测探针，求出处理对象5的尺寸和形状。 [0132] Moreover, the observation probe 107 can be substituted used as an imaging probe light detection probe, processed to obtain the size and shape of 5. 例如，通过使用用于取得光相干断层图像（OCT :0ptical CoherentTomography)的光CT探针作为光检测探针，尽管在当前时刻深度的界限是数mm程度，然而能把握肿瘤尺寸和形状（参照非专利文献4)。 For example, by using an optical coherence tomographic image for acquiring (OCT: 0ptical CoherentTomography) CT probe light as the light detection probe, although at the present time is to limit the depth of several mm, but can grasp the tumor sizes and shapes (see Non- Patent Document 4). 并且，例如可以使用荧光探针作为光检测探针，该突光探针使用与DHE (dihematoporphyrin ether, 二血卩卜啉醚)结合的抗CEA (cacinoembryonic antigen,癌胚胎抗原）单克隆抗体（参照专利文献2)来检测由激励产生的突光。 And, for example, fluorescent probes can be used as an optical detection probe, using the projection optical probe DHE (dihematoporphyrin ether, morpholine two blood Jie Bu ether) anti-CEA (cacinoembryonic antigen, carcinoembryonic antigen) monoclonal antibody (see Patent Document 2) to detect the light produced by projecting excitation. 另外，作为荧光的发光分子，可以采用Qdot (R)(参照非专利文献5)。 Further, the light-emitting fluorescent molecule may be employed Qdot (R) (refer to Non-Patent Document 5). 可以使Qdot (R)与进行癌特异性结合的单克隆抗体结合。 Can Qdot (R) monoclonal antibody binding to cancer-specific binding. 使荧光结合的分子也不限于抗体，可以使用蛋白质和肽、核酸等。 Fluorescent molecules bound antibody is not limited to, proteins and peptides may be used, and other nucleic acids. 并且，作为突光分子，可列举以下：AMCA, SpectrumAqua, FITC, FAM, Rhodamin6G, Cy(R)3, TRITC, TAMRA, Lissamin(R)rhodamineB，Texas Red(R)，Cy(R)5, Cy(R)5. 5,Alexa Fluor (R)350, Pacific Blue (R), Oregon Green (R)488, Alexa Fluor (R)488,Alexa Fluor(R)532,Alexa Fluor(R)546,Alexa Fluor(R)555,Alexa Fluor(R)568,AlexaFluor (R) 594, Alexa Fluor (R) 647, Alexa Fluor (R) 660, Alexa Fluor (R) 680 等。 Further, as the light projecting elements include the following: AMCA, SpectrumAqua, FITC, FAM, Rhodamin6G, Cy (R) 3, TRITC, TAMRA, Lissamin (R) rhodamineB, Texas Red (R), Cy (R) 5, Cy (R) 5. 5, Alexa Fluor (R) 350, Pacific Blue (R), Oregon Green (R) 488, Alexa Fluor (R) 488, Alexa Fluor (R) 532, Alexa Fluor (R) 546, Alexa Fluor (R) 555, Alexa Fluor (R) 568, AlexaFluor (R) 594, Alexa Fluor (R) 647, Alexa Fluor (R) 660, Alexa Fluor (R) 680 and the like. 而且，可以将荧光素酶基因通过媒介物导入到癌细胞内，之后，通过输入荧光素进行使其激励的反应来使其发光，将接收该发出的光的发光探针用作光检测探针。 Further, the luciferase gene can be introduced into the cancer cells by the vehicle, then to emit light by inputting it fluorescein excitation reaction, the probe is used as the light receiving detection probe emitting the light emitted .
[0133] 另外，在本实施方式3中所说的包含成像探针的观察探针107是指所谓的探针，即检测对象物的特性的检测器，与在生物医疗系统中使用的分子探针（能阐明和检索活体功能、或者能识别特定分子的分子总称）不同。 [0133] Further, in the present embodiment of said embodiment of the observation probe 3 comprises an imaging probe 107 refers to a so-called probe, i.e. a detector detecting the object properties, and molecular probe for use in biomedical systems needle (shed light and retrieval functions of living bodies, or can be a generic term recognition molecule specific molecules) are different.
[0134]另外，采用在上述前端套管104内使观察探针107和穿刺针110交替插拔的结构，然而不限于此，前端套管104可以具有多通道的引导孔。 [0134] Further, making use of the observation probe 107 and the puncture needle 110 are alternately plug structure in said front end of the sleeve 104, but is not limited thereto, the end cannula 104 may have guide holes multiple channels. 在该情况下，在各引导孔内设置上述编码器Illa〜llld。 In this case, the encoder Illa~llld disposed in each guide bore.
[0135] 并且，上述的编码器111和标志107a、110a分别使用了磁，然而不限于此，可以使用光学式、静电电容式等的任意检测单元。 [0135] Further, the above-described encoder 111 and flags 107a, 110a, respectively, using magnetic, but not limited thereto, may be used an optical type, a capacitance type or the like of any detection means. 并且，也不限于线性编码器，可以使用检测从动于观察探针107、穿刺针110的插拔、转动的球、棍的旋转的单元。 Further, not limited to a linear encoder, it can be used to detect the driven observation probe 107, the puncture needle 110 of the plug, the rotation of the ball, rotation of the stick unit.
1. 一种药液投给系统，该药液投给系统向包括人在内的哺乳类供给药液，所述药液投给系统的特征在于，所述药液投给系统具有： 药液供给装置，其供给药液； 观察装置，其具有观察被投给药液的患部的细长的观察探针；以及药液投给用套管，其至少一部分被嵌入到体内， 所述药液投给用套管将从所述药液供给装置供给的所述药液和所述观察探针引导到所述患部； 所述药液投给用套管的被投给所述药液的通道和被插入所述观察探针的通道是通用的同一通道，所述药液投给用套管在不同的时机进行所述药液的投给和使用所述观察探针的观察。 A medicinal-solution administration system, the chemical liquid supply system solution administration to a mammal, including a human, the medicinal-solution administration system is characterized in that the medicinal-solution administration system comprising: a liquid supply means for supplying liquid; observation means having an elongated observation probe to the diseased part observation medicinal solution is administered; and solution administration cannula, which is at least partially embedded into the body, the chemical administration cannula from said chemical liquid supply means supplying the liquid and the observation probe to the diseased part; solution administration cannula is administering the medicinal solution passage and a channel for inserting the observation probe are common to the same channel observed by the observation probe and cannula for administration of the chemical liquid for use in different timings solution administration.
2.根据权利要求I所述的药液投给系统，其特征在于，所述药液投给用套管具有侧面开口部，并从该侧面开口部向所述患部投给所述药液。 2. The drug solution according to claim I of the administration system, wherein the medicinal-solution administration cannula has a side opening portion, and cast from the side to the opening portion of the liquid to the diseased part.
3.根据权利要求2所述的药液投给系统，其特征在于，所述药液投给用套管在所述侧面开口部的附近设有由所述观察探针进行检测的标志。 According to claim 2, wherein said liquid administration system, wherein the medicinal-solution administration cannula has a marker is detected by the observation probe in the vicinity of the side surface of the opening portion.
4.根据权利要求3所述的药液投给系统，其特征在于，所述观察探针是超声波探针， 所述标志反射由所述超声波探针发出的超声波。 According to claim 3, wherein said liquid administration system, wherein the observation probe is an ultrasonic probe, the marker reflects ultrasound generated by the ultrasound probe.
5.根据权利要求4所述的药液投给系统，其特征在于，所述标志是气泡。 The drug solution according to claim 4, wherein the administration system, wherein the marker is a bubble.
6.根据权利要求2所述的药液投给系统，其特征在于，所述药液投给用套管能以该药液投给用套管的轴为中心转动。 The drug solution administration system according to claim 2, wherein the medicinal-solution administration cannula to the drug solution can be administered to the rotary shaft as the center of the sleeve.
7.根据权利要求2所述的药液投给系统，其特征在于，所述侧面开口部在周向上设有多个。 7. The liquid according to claim 2, administration system, characterized in that said side opening portion provided in the circumferential direction a plurality.
8.根据权利要求2所述的药液投给系统，其特征在于，所述观察探针在被收容于所述药液投给用套管内被插入该观察探针的通道内的状态下，能以该观察探针的轴为中心转动。 According to claim 2, wherein said liquid administration system, wherein the observation state in the probe is received in the medicinal-solution administration cannula is inserted into the inner passage of the observation probe, rotational energy to the center axis of the observation probe.
9.根据权利要求I所述的药液投给系统，其特征在于，所述观察探针是超声波探针，并具有： 设在所述超声波探针前端的气球，以及将流体插入到所述气球内的插入单元。 9. The drug solution according to claim I administration system, wherein the observation probe is an ultrasonic probe, and comprising: an ultrasonic probe arranged in the distal end of the balloon, and is inserted into the fluid the balloon insertion unit.
10.根据权利要求I所述的药液投给系统，其特征在于，所述观察探针是成像探针。 10. The drug solution according to claim I of the administration system, wherein the observation probe is an imaging probe.
11.根据权利要求10所述的药液投给系统，其特征在于，所述成像探针一并使用造影剂。 11. The drug solution according to claim 10 administered to a system, wherein the imaging probe is a contrast agent together.
12.根据权利要求10所述的药液投给系统，其特征在于，所述成像探针是荧光探针。 12. The drug solution according to claim 10, said administration system, wherein the imaging probe is a fluorescent probe.
13.根据权利要求10所述的药液投给系统，其特征在于，所述成像探针是发光探针。 13. The drug solution according to claim 10, said administration system, wherein the imaging probe is a luminescent probe.
14.根据权利要求10所述的药液投给系统，其特征在于，所述成像探针是超声波探针。 14. The drug solution according to claim 10, said administration system, wherein the imaging probe is an ultrasonic probe.
15.根据权利要求I所述的药液投给系统，其特征在于，所述观察探针是生物传感器探针。 15. The drug solution according to claim I of the administration system, wherein the observation probe is a bio-sensor probe.
16.根据权利要求I所述的药液投给系统，其特征在于，所述观察探针具有标志， 所述药液投给用套管具有检测部，该检测部在被插入所述观察探针的通道内检测所述O 16. The drug solution according to claim I of the administration system, wherein the observation probe includes a marker, the medicinal-solution administration cannula includes a detecting portion, the detection portion is inserted into the observation probe detecting within said needle passageway O
17.根据权利要求16所述的药液投给系统，其特征在于，所述检测部检测所述观察探针相对于所述药液投给用套管的轴的相对的周向和相对的推力方向的位置。 17. The drug solution according to claim 16 for administration system, wherein the detecting unit detects the observation probe relative to opposing circumferential axis of the medicinal-solution administration cannula and relative to the the position of the thrust direction.
18.根据权利要求16所述的药液投给系统，其特征在于，所述标志是磁标志。 18. The drug solution according to claim 16, said administration system, wherein said marker is a magnetic marker.
19.根据权利要求I所述的药液投给系统，其特征在于，所述药液投给系统具有细长的穿刺针，该穿刺针被插入到所述药液投给用套管内，并投给所述药液， 所述穿刺针具有标志， 所述药液投给用套管具有检测部，该检测部在被插入所述穿刺针的通道内检测所述标O 19. The drug solution according to claim I of the administration system, wherein the medicinal-solution administration system having an elongated puncture needle, the puncture needle is inserted into the inner tube solution administration, and administering the medicinal solution, the puncture needle includes a marker, the medicinal-solution administration cannula includes a detecting unit, the detecting unit detects the mark O in the puncture needle is inserted into the channel
20.根据权利要求19所述的药液投给系统，其特征在于，所述检测部检测所述穿刺针相对于所述药液投给用套管的轴的相对的周向和相对的推力方向的位置。 20. The medicinal-solution administration system according to claim 19, characterized in that the opposite circumferential portion of the detecting detects the puncture needle with respect to an axis of the medicinal-solution administration cannula and a relative thrust direction position direction.
21.根据权利要求19所述的药液投给系统，其特征在于，所述标志是磁标志。 21. The drug solution according to claim 19 for administration system, wherein said marker is a magnetic marker.
22.根据权利要求19所述的药液投给系统，其特征在于，所述穿刺针在前端附近具有自由弯曲的弯曲部。 22. The drug solution according to claim 19 for administration system, wherein the puncture needle has a curved portion in the vicinity of the free front end is bent.
23.根据权利要求19所述的药液投给系统，其特征在于，所述穿刺针是由至少2个以上的导管构成的多层导管，内侧导管在外侧导管的轴线方向上自由滑动地被插入，内侧导管能够从外侧导管的前端部自由突出，在至少I个导管的前端部形成有弯曲部，内侧导管具有比外侧导管小的弯曲刚性，所述弯曲部弯曲形成为使内侧导管在所述外侧导管内处于能弹性变形的弹性限度内。 23. The medicinal-solution administration system according to claim 19, wherein the puncture needle is a multi-layer pipe formed with at least two of the catheter, the inner catheter slidably in the axial direction of the outside of the catheter is insertion, the catheter can project from the inner end of the outer conduit free, formed in at least a distal portion of the catheter I bent portion, the inner conduit having a smaller flexural rigidity than the outer pipe, the bent portion formed by bending the inner conduit to the said outer catheter is within the elastic limit of the elastically deformable.
24.根据权利要求19所述的药液投给系统，其特征在于，所述观察装置显示输出由所述检测部检测出的所述穿刺针相对于所述药液投给用套管的轴的相对的周向和相对的推力方向的位置。 24. The medicinal-solution administration system according to claim 19, wherein said needle display output device detected by the detecting portion of the shaft with respect to the medicinal-solution administration cannula the observation position and an opposite circumferential direction opposite to the thrust direction.
25.根据权利要求19所述的药液投给系统，其特征在于，所述观察装置的显示输出是将所述药液投给用套管的位置和所述穿刺针相对于该药液投给用套管的相对位置重叠在所述患部的观察结果上进行显示。 25. The medical fluid administration system according to claim 19, wherein said output means is display observation administered to the liquid and to position said needle cannula with respect to the medicinal-solution administration the relative position of the cannula is superimposed on the observation result of the diseased part is displayed.
26.根据权利要求I所述的药液投给系统，其特征在于，所述药液供给装置具有： 药液贮存器，其至少贮存药液，并将该药液供给到药液投给侧； 可变流量泵，其将压出所述药液贮存器内的药液的驱动液可变地排出到所述药液贮存器； 驱动液贮存器，其贮存所述驱动液；以及控制单元，其控制所述可变流量泵的排出流量，使得每单位时间的药液投给量成为期望投给量。 26. The drug solution according to claim I of the administration system, wherein said chemical liquid supply apparatus comprising: a liquid reservoir that accommodates at least medicinal solution, and the liquid is supplied to the solution administration side ; variable flow pump, which was driven out of the liquid pressure within the liquid reservoir is discharged to the variable chemical reservoir; drive-liquid reservoir, which store the driving liquid; and a control unit controlling the discharge flow rate of the variable flow pump so that the chemical liquid per unit time becomes a desired amount of administration to a given amount administered.
CN2008801062135A 2007-10-31 2008-10-31 Drug solution-administration system and cannula for administering drug solution CN101801436B (en)
JP2007-284468 2007-10-31
JP2007284468 2007-10-31
JP2008119950 2008-05-01
JP2008-119950 2008-05-01
PCT/JP2008/069935 WO2009057774A1 (en) 2007-10-31 2008-10-31 Drug solution-administration system and cannula for administering drug solution
CN101801436A CN101801436A (en) 2010-08-11
CN101801436B true CN101801436B (en) 2012-10-24
ID=40591154
CN2008801062135A CN101801436B (en) 2007-10-31 2008-10-31 Drug solution-administration system and cannula for administering drug solution
US (1) US20100198048A1 (en)
EP (1) EP2213318A4 (en)
JP (1) JP5244815B2 (en)
CN (1) CN101801436B (en)
WO (1) WO2009057774A1 (en)
JP5361488B2 (en) 2009-03-24 2013-12-04 オリンパス株式会社 Fluorescence observation apparatus
JP5698483B2 (en) * 2010-09-22 2015-04-08 オリンパス株式会社 Fluorescence observation apparatus
JP5803354B2 (en) * 2010-10-08 2015-11-04 セイコーエプソン株式会社 The fluid ejection device and medical devices
CN105992608B (en) * 2013-12-05 2019-01-15 弗罗桑医疗设备股份公司 Echo inlying catheter
JP4222819B2 (en) * 2002-11-20 2009-02-12 オリンパス株式会社 Balloon with an ultrasonic probe
JP2006167298A (en) 2004-12-17 2006-06-29 Japan Health Science Foundation Multilayer conduit, multilayer conduit driving apparatus, and multilayer conduit driving system
2008-10-31 CN CN2008801062135A patent/CN101801436B/en not_active IP Right Cessation
2008-10-31 EP EP08843356A patent/EP2213318A4/en not_active Withdrawn
2008-10-31 JP JP2009539138A patent/JP5244815B2/en active Active
2008-10-31 WO PCT/JP2008/069935 patent/WO2009057774A1/en active Application Filing
2010-04-07 US US12/755,541 patent/US20100198048A1/en not_active Abandoned
JP特开2000-14663A 2000.01.18
JP特开2003-88527A 2003.03.25
JPWO2009057774A1 (en) 2011-03-10
EP2213318A1 (en) 2010-08-04
WO2009057774A1 (en) 2009-05-07
CN101801436A (en) 2010-08-11
EP2213318A4 (en) 2011-03-09
US20100198048A1 (en) 2010-08-05
JP5244815B2 (en) 2013-07-24
Itoi et al. 2005 Puncture of solid pancreatic tumors guided by endoscopic ultrasonography: a pilot study series comparing Trucut and 19-gauge and 22-gauge aspiration needles
US20010016760A1 (en) 2001-08-23 Use of 5-aminolevulinic acid or a derivate thereof for photodynamic diagnosis and/or photodynamic therapy
JP4709836B2 (en) 2011-06-29 Autonomous body device
Swain et al. 1994 An endoscopically deliverable tissue-transfixing device for securing biosensors in the gastrointestinal tract